HUP0402298A2 - Dezoxipeganin alkalmazása klinikai depresszió kezelésére - Google Patents

Dezoxipeganin alkalmazása klinikai depresszió kezelésére

Info

Publication number
HUP0402298A2
HUP0402298A2 HU0402298A HUP0402298A HUP0402298A2 HU P0402298 A2 HUP0402298 A2 HU P0402298A2 HU 0402298 A HU0402298 A HU 0402298A HU P0402298 A HUP0402298 A HU P0402298A HU P0402298 A2 HUP0402298 A2 HU P0402298A2
Authority
HU
Hungary
Prior art keywords
desoxypeganine
clinical depression
treating clinical
depression
treating
Prior art date
Application number
HU0402298A
Other languages
English (en)
Inventor
Joachim Moormann
Hermann Mucke
Original Assignee
Hf Arzneimittelforschung Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hf Arzneimittelforschung Gmbh filed Critical Hf Arzneimittelforschung Gmbh
Publication of HUP0402298A2 publication Critical patent/HUP0402298A2/hu
Publication of HUP0402298A3 publication Critical patent/HUP0402298A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms

Abstract

(57) Dezoxipeganin alkalmazása szabad bázisként vagy savaddícióssóként a klinikai depresszió kezelésére alkalmas gyógyszerekelőállítására különösen a dementiával vagy az alkohollal és/vagynikotinnal történő visszaéléssel kapcsolatos depresszióra. Ó
HU0402298A 2001-12-21 2002-12-14 Use of desoxypeganine for treating clinical depression HUP0402298A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10163667A DE10163667B4 (de) 2001-12-21 2001-12-21 Verwendung von Desoxypeganin zur Behandlung der klinischen Depression
PCT/EP2002/014274 WO2003053445A1 (de) 2001-12-21 2002-12-14 Verwendung von desoxypeganin zur behandlung der klinischen depression

Publications (2)

Publication Number Publication Date
HUP0402298A2 true HUP0402298A2 (hu) 2005-02-28
HUP0402298A3 HUP0402298A3 (en) 2011-03-28

Family

ID=7710660

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0402298A HUP0402298A3 (en) 2001-12-21 2002-12-14 Use of desoxypeganine for treating clinical depression

Country Status (30)

Country Link
US (1) US20050009813A1 (hu)
EP (1) EP1461042B1 (hu)
JP (1) JP2005513105A (hu)
KR (1) KR100614504B1 (hu)
CN (1) CN1283253C (hu)
AR (1) AR037967A1 (hu)
AT (1) ATE404203T1 (hu)
AU (1) AU2002363874B2 (hu)
BR (1) BR0215306A (hu)
CA (1) CA2471338C (hu)
CZ (1) CZ301210B6 (hu)
DE (2) DE10163667B4 (hu)
DK (1) DK1461042T3 (hu)
EA (1) EA006896B1 (hu)
ES (1) ES2312657T3 (hu)
HK (1) HK1066742A1 (hu)
HU (1) HUP0402298A3 (hu)
IL (2) IL162509A0 (hu)
MX (1) MXPA04006125A (hu)
MY (1) MY138088A (hu)
NO (1) NO326446B1 (hu)
NZ (1) NZ533249A (hu)
PL (1) PL370315A1 (hu)
PT (1) PT1461042E (hu)
SI (1) SI1461042T1 (hu)
SK (1) SK287152B6 (hu)
TW (1) TWI241189B (hu)
UA (1) UA76254C2 (hu)
WO (1) WO2003053445A1 (hu)
ZA (1) ZA200404053B (hu)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE521512C2 (sv) * 2001-06-25 2003-11-11 Niconovum Ab Anordning för administrering av en substans till främre delen av en individs munhåla
WO2004056363A2 (en) 2002-12-20 2004-07-08 Niconovum Ab A physically and chemically stable nicotine-containing particulate material
DE10354893B4 (de) * 2003-11-24 2011-03-10 Hf Arzneimittelforschung Gmbh Verwendung von Desoxypeganin zur Behandlung schizophrener Psychosen
DE10354894A1 (de) * 2003-11-24 2005-07-07 Hf Arzneimittelforschung Gmbh Orale Formulierungen des Desoxypeganins und deren Anwendungen
FR2865650B1 (fr) * 2004-01-30 2008-06-13 Biocortech Utilisation du 14,15 dihydro 20,21-dinoreburnamenin14-ol pour traiter et/ou prevenir les depressions majeures et les desordres du cycle veille-sommeil
JP5000932B2 (ja) * 2005-06-21 2012-08-15 日東電工株式会社 ニコチン含有経皮吸収製剤
CA2646942C (en) 2006-03-16 2014-07-29 Niconovum Ab Improved snuff composition
CN101433565B (zh) * 2008-11-26 2013-06-05 上海中医药大学 骆驼蓬属种子总生物碱提取物和它们的制备

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19906979B4 (de) * 1999-02-19 2004-07-08 Lts Lohmann Therapie-Systeme Ag Verwendung von Desoxypeganin zur Behandlung der Nikotinabhängigkeit
DE19906977C1 (de) * 1999-02-19 2000-06-15 Lohmann Therapie Syst Lts Desoxypeganin-TTS und seine Verwendung
DE19906975B4 (de) * 1999-02-19 2004-04-15 Lts Lohmann Therapie-Systeme Ag Arzneiform zur Behandlung von Alzheimer'scher Demenz
DE19906978B4 (de) * 1999-02-19 2004-07-08 Lts Lohmann Therapie-Systeme Ag Pharmazeutische Zusammensetzung enthaltend Desoxypeganin zur Behandlung der Drogenabhängigkeit
DE19906974C2 (de) * 1999-02-19 2003-10-09 Lohmann Therapie Syst Lts Verwendung von Desoxypeganin zur Behandlung des Alkoholismus

Also Published As

Publication number Publication date
NO20042476L (no) 2004-06-14
IL162509A (en) 2010-06-16
SI1461042T1 (sl) 2009-02-28
DK1461042T3 (da) 2008-12-01
CA2471338A1 (en) 2003-07-03
WO2003053445A1 (de) 2003-07-03
JP2005513105A (ja) 2005-05-12
NO326446B1 (no) 2008-12-08
MXPA04006125A (es) 2005-05-16
KR100614504B1 (ko) 2006-08-22
ES2312657T3 (es) 2009-03-01
ZA200404053B (en) 2004-10-12
DE10163667B4 (de) 2006-10-26
CN1283253C (zh) 2006-11-08
NZ533249A (en) 2007-05-31
ATE404203T1 (de) 2008-08-15
AU2002363874B2 (en) 2007-12-13
CA2471338C (en) 2009-02-24
EA200400751A1 (ru) 2004-12-30
US20050009813A1 (en) 2005-01-13
WO2003053445A8 (de) 2004-07-01
TWI241189B (en) 2005-10-11
TW200301124A (en) 2003-07-01
EA006896B1 (ru) 2006-04-28
PL370315A1 (en) 2005-05-16
MY138088A (en) 2009-04-30
PT1461042E (pt) 2008-11-03
HUP0402298A3 (en) 2011-03-28
EP1461042B1 (de) 2008-08-13
CN1604781A (zh) 2005-04-06
IL162509A0 (en) 2005-11-20
CZ301210B6 (cs) 2009-12-09
DE50212649D1 (de) 2008-09-25
SK287152B6 (sk) 2010-01-07
DE10163667A1 (de) 2003-07-10
AU2002363874A1 (en) 2003-07-09
HK1066742A1 (en) 2005-04-01
UA76254C2 (en) 2006-07-17
BR0215306A (pt) 2004-12-21
KR20040068327A (ko) 2004-07-30
SK2582004A3 (en) 2004-12-01
CZ2004739A3 (cs) 2004-12-15
AR037967A1 (es) 2004-12-22
EP1461042A1 (de) 2004-09-29

Similar Documents

Publication Publication Date Title
HUP0104709A2 (hu) Eritropoietin vagy eritropoietrinszármazékok alkalmazása agyi iszkémiák kezelésére használható gyógyszer előállítására
NO324227B1 (no) Cyclopropyl-kondenserte pyrrolidin-baserte forbindelser, farmasoytiske blandinger og kombinasjoner inneholdende slike samt anvendelse av slike for fremstilling av medikamenter for behandling av sykdommer
ATE292971T1 (de) (s,s)-reboxetin zur behandlung von peripheren neuropathien
HK1087398A1 (en) 1-phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases
CY1110745T1 (el) Παραγωγα πυρρολιδονης ως αναστολεις μαοβ
EE05419B1 (et) Asendatud oksasolidinoonid kombineeritud raviks
DE60231804D1 (de) Verwendung von hepcidin zur herstellung eines arzneimittels zur behandlung von eisenhomöostase störungen
CY1109361T1 (el) Υποκατεστημενες 4-αμινοκυκλοεξανολες
HUP0402298A2 (hu) Dezoxipeganin alkalmazása klinikai depresszió kezelésére
HUP0300972A2 (hu) Gatifloxacin-pentahidrát
HUP0204520A2 (en) Pharmaceutical composition containing esmolol and process for its preparation
HUP0203197A2 (hu) Docetaxel alkalmazása hepatocelluláris karcinómák kezelésére
MXPA04001419A (es) Isoxazolopiridinonas y su uso en el tratamiento de enfermedad de parkinson.
HUP0304050A2 (hu) Módosított FVII az ARDS kezelésre
NO970573L (no) Ylidenforbindelser og deres fremstilling
HUP0202324A2 (hu) Prukaloprid orális oldat
AU2003245989A1 (en) Pharmaceutical compositions of anticholinergics and p38 kinase inhibitors in the treatment of respiratory diseases
PT1406859E (pt) Derivados substituídos de 4-aminociclo-hexanol
CA2436537A1 (en) Pharmaceutical compositions comprising tiotropium salts and antihistamines
DE60027282D1 (de) Verwendung von l-threo-methylphenidate zur Herstellung eines Medikaments für die Behandlung von Depression
NO20040471L (no) 5,6,6a,1 1b-tetrahydro-7-oksa-5-azabenzo[c]fluoren-6-karboksylsyrederivater som NMDA-antagonister
ATE345124T1 (de) Verwendung von l-acetylcarnitin zur herstellung eines medikaments zur behandlung von anhedonia
WO2002072527A3 (de) 1-butansäurederivate wie z.b. carbomethoxypropionylcyanid oder leflunomidderivate und deren therapeutische anwendung
WO2003027295A3 (en) Methods for diagnosis and treatment of diseases associated with altered expression of jak1
CA2430592A1 (en) New pharmaceutical compositions based on anticholinergics and dopamine agonists

Legal Events

Date Code Title Description
FA9A Lapse of provisional patent protection due to relinquishment or protection considered relinquished